G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 12.94 CNY -6.71% Market Closed
Market Cap: 5.3B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GemPharmatech Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Cash from Operating Activities
ÂĄ116.6m
CAGR 3-Years
-4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Operating Activities
ÂĄ12.8B
CAGR 3-Years
40%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Operating Activities
ÂĄ2.6B
CAGR 3-Years
11%
CAGR 5-Years
24%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Operating Activities
ÂĄ3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-4%
CAGR 5-Years
15%
CAGR 10-Years
37%
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Operating Activities
ÂĄ332.8m
CAGR 3-Years
262%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.3B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
20.3 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
116.6m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Cash from Operating Activities amounts to 116.6m CNY.

What is GemPharmatech Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
22%

Over the last year, the Cash from Operating Activities growth was 10%. The average annual Cash from Operating Activities growth rates for GemPharmatech Co Ltd have been -4% over the past three years , 22% over the past five years .

Back to Top